Who is sponsoring NCT02595723?

NCT02595723 is sponsored by University of Texas Southwestern Medical Center.

What condition does NCT02595723 study?

NCT02595723 studies Cognitive Impairment.

What drugs are being tested in NCT02595723?

Interventions: Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo.

What is the status of NCT02595723?

NCT02595723 is currently COMPLETED.

Last reviewed 2019-09-06 · How we verify

Phenytoin for Memory Impairment Secondary to Megestrol

NCT02595723 Phase 4 COMPLETED Results posted

This study is designed to test if megestrol acetate induces changes in declarative memory in healthy controls and if pre-administration of phenytoin can ameliorate any induced cognitive impairments.

Details

Lead sponsor	University of Texas Southwestern Medical Center
Phase	Phase 4
Status	COMPLETED
Enrolment	21
Start date	2015-07
Completion	2016-12

Conditions

Cognitive Impairment

Interventions

Phenytoin 200 mg capsule
Megestrol 800 mg liquid
Phenytoin-matched Placebo capsule
Megestrol-matched liquid Placebo

Primary outcomes

Rey Auditory Verbal Learning Test (RAVLT) — 4 days after intervention administration
Rey Auditory Verbal Learning Test (RAVLT) is a test of verbal learning and declarative memory. During the test, 15 nouns that are read aloud for 5 consecutive trials. Each trial is followed by a free recall test (participant is asked to recall the words that were just read to them). The sum of correctly recalled words across 5 trials is called the total raw score. The raw scores on the total recall (number of words correct across trials 1-5) are converted to standardized T-scores (Mean=50; SD=10; range 20-100) based on participant age and gender. The scores below are presented as T-scores, with higher scores indicative of better performance.

Countries

United States